Core Viewpoint - InnoCare Pharma-B (09606) shares rose by 10.19% to HKD 339.40, with a trading volume of HKD 135 million, following the announcement of Fast Track Designation (FTD) by the FDA for its new generation HER3-targeted antibody-drug conjugate DB-1310 for specific breast cancer patients [1] Group 1 - The FDA granted Fast Track Designation to DB-1310 for the treatment of adult patients with HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and CDK4/6 inhibitor treatment, and are in the stage of unresectable or metastatic disease [1] - DB-1310 is the first HER3-ADC drug to receive FTD for this indication globally, indicating a significant milestone for the company [1] - The broad FTD indication for DB-1310 will facilitate its clinical development in both chemotherapy-naive and chemotherapy-resistant settings for HR+/HER2- breast cancer [1]

智通财经APP获悉，映恩生物-B(09606)早盘涨超3%，截至发稿，涨3.25%，报318港元，成交额2339.55 万港元。 消息面上，据映恩生物官微消息，12月18日，映恩生物宣布，美国食品药品监督管理局(FDA)已授予映 恩生物新一代靶向HER3抗体偶联新药DB-1310快速通道资格认定(Fast Track Designation，FTD)，用于 治疗曾接受过内分泌治疗、CDK4/6抑制剂治疗，且在不可切除或转移性疾病阶段接受或未接受过化 疗，或在完成辅助化疗期间或结束后6个月内出现疾病复发的成人晚期/不可切除或转移性激素受体(HR) 阳性、人表皮生长因子受体2(HER2)阴性(免疫组化0、1+或2+/原位杂交阴性)乳腺癌患者。 据悉，DB-1310成为全球首款在此适应症上获FTD的HER3-ADC药物。DB-1310在HR+/HER2-乳腺癌中 的FTD适应症范围较广，涵盖"在不可切除或转移性疾病阶段接受或未接受过化疗"的患者。这一广阔适 应症的FTD认定将有助于推动DB-1310在HR+/HER2-乳腺癌未经化疗前线场景与化疗耐药后线场景两条 主要路径上的关键临床开发。 ...

Core Viewpoint - InnoCare Pharma-B (09606) experienced a morning increase of over 3%, currently up 3.25% at HKD 318, with a trading volume of HKD 23.3955 million. The company announced that the FDA has granted Fast Track Designation (FTD) for its next-generation HER3-targeted antibody-drug conjugate DB-1310, aimed at treating adult patients with advanced or unresectable metastatic hormone receptor-positive (HR+), HER2-negative breast cancer who have previously undergone endocrine therapy and CDK4/6 inhibitor treatment, or have experienced disease recurrence within six months after completing adjuvant chemotherapy [1]. Group 1 - The FDA has granted Fast Track Designation to DB-1310, making it the first HER3-ADC drug to receive this designation for the specified indication [1]. - The FTD designation for DB-1310 covers a broad range of indications in HR+/HER2- breast cancer, including patients who have received or not received chemotherapy during the stage of unresectable or metastatic disease [1]. - This broad indication will facilitate the critical clinical development of DB-1310 in both pre-chemotherapy frontline scenarios and post-chemotherapy resistant scenarios [1].

Group 1: Core Insights - The pharmaceutical industry is entering a clear upward cycle with significant growth opportunities in innovative drugs and the innovation chain, driven by supportive policies and a global expansion trend [3][10] - The Chinese innovative drug sector is increasingly favored by international capital, with a record high of 149 transactions in 2025, accounting for 11% of global transaction numbers and 29% of total transaction value [10][37] - The introduction of commercial health insurance into the medical insurance negotiation process in 2025 is expected to diversify the payment system for innovative drugs, enhancing their market accessibility [10][37] Group 2: Innovative Drugs - The upward policy cycle supports innovation, with the latest round of drug procurement entering a new phase of quality-price balance, as seen in the 11th batch of centralized procurement [10][30] - The global patent cliff from 2025 to 2037 is projected to create a gap exceeding $300 billion, prompting multinational corporations (MNCs) to pursue business development (BD) and acquisitions to fill this gap [10][45] - Chinese innovative drugs are positioned to capitalize on this trend, particularly in areas such as second-generation immune-oncology (IO) and next-generation antibody-drug conjugates (ADCs) [10][50] Group 3: Innovation Chain - The innovation chain, including Contract Development and Manufacturing Organizations (CDMO) and Contract Research Organizations (CRO), is benefiting from both domestic and international demand, with CDMO orders showing a positive growth trend [12][12] - The overseas biopharmaceutical investment environment is improving, with a notable increase in funding as interest rates decline, which is expected to enhance the overall industry cycle [12][12] - The life sciences service sector is witnessing a recovery, driven by increasing domestic research demand and improved conditions for innovative drug development [12][13] Group 4: Market Opportunities - The domestic market for innovative drugs is projected to grow significantly, with over 400 innovative drugs approved since 2020, indicating strong internal growth potential [62][66] - As innovative drug companies transition to profitability, there is a potential shift in valuation methods from P/Peak Sales to PE, attracting broader investment interest [66] - Key companies to watch include AiLisi, Yunding Xinyao, and Kangnuo Ya, which are expected to benefit from the commercialization of innovative products [66]

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

Core Viewpoint - The article presents an interview with Yang Yunxia, a partner at Sequoia China, who discusses the value judgment framework for the next stage of the biopharmaceutical industry, emphasizing that Biotech will remain a mainstream investment direction in healthcare, particularly focusing on the iteration of "second-generation technology paradigms" [4][7]. Group 1: Investment Trends and Opportunities - Biotech is highlighted as a key investment direction, with a focus on advancements such as ADC drugs evolving from single-target to dual-target and the development of more complex antibody technologies [7][8]. - The Chinese biopharmaceutical industry is transitioning from being a global observer to a significant participant, characterized by strong iteration capabilities and efficient execution [9][10]. - By 2024, China is expected to account for 18% of the global share of new molecular entities, ranking as the second-largest country for new drug listings [9]. Group 2: Market Dynamics and Challenges - The overall pharmaceutical industry saw a 16.72% increase from early 2025 to November, outperforming the CSI 300 index by 1.68 percentage points, driven by breakthroughs in innovative drugs and active business development (BD) transactions [7]. - The article notes that while there are many opportunities, the industry must also confront challenges, including the need for improved commercialization capabilities and the risk of resource wastage due to blind competition [10][11]. Group 3: Strategic Insights for Investment - Yang Yunxia emphasizes the importance of selecting early-stage projects based on two criteria: the team and the asset, which are crucial for maximizing value returns [15]. - The article discusses the significance of BD transactions as a means to enhance capital, brand, and capabilities, which are essential for the growth of Biotech companies [11][12]. - It is noted that the pricing of Chinese Biotech assets in overseas transactions is often lower, highlighting the need for a shift in perception regarding the value of Chinese assets in global markets [11][12]. Group 4: Future Outlook - Yang Yunxia maintains an optimistic yet cautious outlook on the capital market cycle for 2026, emphasizing that the core standard for assessing enterprise value lies in fundamentals [8][14]. - The article concludes that the Chinese biopharmaceutical industry must focus on quality, differentiate its offerings, and balance speed with value to strengthen its competitive position globally [15].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Investment Rating - The report does not explicitly provide an investment rating for the biopharmaceutical sector [5]. Core Insights - The biopharmaceutical sector is experiencing significant activity with multiple companies focusing on innovative drug development, particularly in the area of siRNA targeting INHBE, which shows promise for fat reduction without muscle loss [3][24]. - The report highlights the recent performance of new drug stocks, with notable gains from companies such as Saint Nor Pharmaceutical (+30.88%) and Dongyao Pharmaceutical (+16.37%), while companies like Kexin Pharmaceutical (-14.19%) and Rongchang Biotechnology (-10.09%) faced declines [1][15]. - There is an expectation of multiple catalysts in the sector, including academic conferences and data releases, which could drive further interest and investment [2]. Weekly New Drug Market Review - From December 8 to December 14, 2025, the new drug sector saw significant stock movements, with the top five gainers and losers listed [1][15]. - The report notes that there were no new drug approvals during this week, but 11 new drug applications were accepted [4][31]. Weekly New Drug Industry Analysis - Wave Life Sciences has reported promising initial data for its siRNA drug WVE-007, which targets INHBE and demonstrates potential for reducing visceral fat while preserving muscle mass [3][24]. - The report indicates that several companies, both globally and domestically, are actively developing siRNA drugs targeting INHBE, with five drugs already in clinical development [27][28]. Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but 11 new drug applications were accepted [4][31]. - A total of 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted during the week [9][34]. Key Events in Domestic Market - Significant events include the approval of new drugs by companies such as Zhengda Tianqing and Nuo Cheng Jian Hua, which received approval for their respective new drugs [10][11]. Key Events in Overseas Market - Noteworthy overseas events include Eli Lilly's announcement of positive results from its TRIUMPH-4 Phase 3 trial and the FDA's approval of a gene therapy by Fondazione Telethon [11].

Core Viewpoint - The company Ensign Bio-B (09606) announced a proposed 2025 Share Plan aimed at attracting and retaining key contributors to its long-term development, pending shareholder approval [1] Group 1: 2025 Share Plan Objectives - The 2025 Share Plan is designed to recognize and reward participants for their past contributions to the company [1] - It aims to provide participants with opportunities to acquire proprietary rights of the company, encouraging further contributions to enhance the company's value [1] - The plan offers a flexible approach for the company to retain, incentivize, reward, and compensate participants, as well as provide benefits [1]

Duality Biotherapeutics, Inc. 映恩生物 （於開曼群島註冊成立的有限公司） （股份代號：9606） 茲委任（姓名） （地址） 或如未能出席，委任（姓名） （地址） 或如未能出席，委任大會主席 （附註2） 作為本人╱吾等的委任代表，出席本公司謹訂於2025年12月30日（星期二）上午九 時正假座中國上海市浦東新區櫻花路868號A座11樓董事會會議室舉行的股東特別大會（「股東特別大會」）及其任何續 會，並就會上的任何決議案或就此提呈的動議代表本人╱吾等投票。本人╱吾等授權及指示委任代表，按指示 （附註3） 對以下決議案進行投票： | | 普通決議案 | 贊成 | （附註3） | 反對 | （附註3） | | --- | --- | --- | --- | --- | --- | | 1. | 省覽及批准建議採納2025年股份計劃 | | | | | | 2. | 省覽及批准2025年股份計劃的計劃授權上限 | | | | | | 3. | 省覽及批准2025年股份計劃的服務提供商分項上限 | | | | | 日期：2025年 月 日 簽署 2025年12月30日舉行的股東特別大會適用的 ...